IGF1R+ Mesenchymal Stem Cells for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis lack effective methods for repairing damaged tissues and modulating immune responses, with mesenchymal stem cells offering potential but requiring optimization for specific receptor expression and multipotency maintenance.
Innovation Solution
Administering mesenchymal stem cells expressing insulin-like growth factor 1 receptors (IGF1R), cultured in human cord blood serum, to enhance self-renewal and multipotent differentiation capabilities, allowing for targeted tissue repair and immune modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are used for treating multiple sclerosis, then tissue repair and immune modulation capabilities are improved, but the effectiveness is limited without optimized receptor expression
Solution Approach 1:
The patent changes the parameter of receptor expression by selecting and culturing mesenchymal stem cells that specifically express insulin-like growth factor 1 receptors (IGF1R). This parameter change enhances the cells' ability to respond to IGF1 signals, improving tissue repair effectiveness and immune modulation in multiple sclerosis treatment without adding complex preparation steps.
2Adaptability or versatility
If mesenchymal stem cells are cultured to maintain multipotency, then differentiation capability is improved, but cultivation requirements become more stringent
Solution Approach 1:
The patent uses human cord blood serum as a cultivation medium parameter to maintain the multipotent differentiation capability of mesenchymal stem cells. This specific cultivation parameter allows the cells to retain their ability to differentiate into various cell types while simplifying the cultivation process compared to more complex medium formulations.
Data Source
AI summary
A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.